Jatoi, Aminah <br/><br/>
Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B).  [electronic resource] 

 -  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer  May 2008 
 - 516-20 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1556-1380 
<br/><br/><label>Standard No.: </label>10.1097/JTO.0b013e31816de276  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Boronic Acids--administration & dosage<br/>Bortezomib<br/>Carboplatin--administration & dosage<br/>Cardia--pathology<br/>Disease Progression<br/>Esophageal Neoplasms--drug therapy<br/>Esophagogastric Junction--pathology<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Pyrazines--administration & dosage<br/>Stomach Neoplasms--drug therapy<br/>Survival Rate<br/>Treatment Outcome